XARELTO®: Stroke risk reduction in nonvalvular atrial fibrillation (NVAF)
WHY WOULDN'T YOU CHOOSE A NOAC WITH PROVEN ONCE-DAILY, 24-HOUR STROKE REDUCTION IN PATIENTS WITH ELEVATED RISK?
◇For VTE prophylaxis in acutely ill medical patients at risk for thromboembolic complications who are not at high risk of bleeding.
*Taken with evening meal.
†Patients were considered at an increased risk for stroke if they had a higher CHADS2 score (range 1-6). Patients in ROCKET AF had a mean CHADS2 score of 3.5.
NOAC = non-vitamin K antagonist oral anticoagulant.